Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) is a clinical-stage biopharmaceutical company pioneering non-steroidal therapies for rare endocrine disorders. This page serves as the definitive source for verified news and developments surrounding SPRB's innovative research and clinical programs.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated content includes updates on SPRB's lead candidate tildacerfont for congenital adrenal hyperplasia (CAH), financial disclosures, and scientific conference presentations.
Key information categories include:
- Clinical trial phase updates
- Regulatory agency communications
- Peer-reviewed research publications
- Strategic industry collaborations
- Financial performance summaries
Bookmark this page for direct access to SPRB's official announcements, maintaining informed perspectives on therapeutic advancements in endocrine care.
Spruce Biosciences, Inc. (NASDAQ: SPRB) reported significant developments including surpassing 50% enrollment in its CAHmelia-203 study for adult congenital adrenal hyperplasia (CAH) and a private placement financing of $53.6 million. The company entered an exclusive licensing agreement with Kaken Pharmaceutical for tildacerfont in Japan, receiving a $15 million upfront payment. With cash and investments of $79.1 million by year-end 2022, these funds extend the cash runway into 2025. The company also announced a net loss of $46.2 million for 2022, up from $42.3 million in 2021, amid rising R&D expenses to advance its clinical trials.
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
